Metrizamide inhibits human brain hexokinase

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


The myelographic contrast agent, metrizamide, causes a temporary confusional state in many patients. Since metrizamide is a 2-deoxyglucose analogue, it was tested for inhibitory effects on glucose metabolism. The Michaelis constant (Km) of human brain hexokinase for glucose rose from 0.039 to 0.24 and 0.47 mM with final metrizamide concentrations of 0,16, and 32 mM, respectively. The maximal velocity did not change. Since metrizamide is injected into the human CSF in concentrations of up to 780 mM, impairment of brain glucose metabolism can be expected. These effects could be largely counteracted if metrizamide were injected in a 100 mM glucose solution.

Original languageEnglish (US)
Pages (from-to)884-887
Number of pages4
Issue number8
StatePublished - Aug 1982
Externally publishedYes

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Metrizamide inhibits human brain hexokinase'. Together they form a unique fingerprint.

Cite this